Dabikast-110

Dabikast-110: Dabigatran Etexilate 110 mg Capsules

Dabikast-110 is a pharmaceutical formulation containing Dabigatran Etexilate 110 mg. This product is intended for use under medical supervision for appropriate cardiovascular conditions. If you are looking for reliable information about Dabigatran Etexilate 110 mg, this page provides an overview of its composition, uses, and important precautions.

What is Dabikast-110?

Dabikast-110 contains Dabigatran Etexilate 110 mg, an oral anticoagulant medicine commonly known as a direct thrombin inhibitor. It works by inhibiting thrombin, an enzyme involved in blood clot formation. This action helps reduce the risk of certain harmful blood clots when prescribed for approved medical indications.

Dabigatran Etexilate is used for specific conditions involving blood clot prevention and treatment. The appropriate dose and duration of treatment depend on the patient’s medical condition, kidney function, age, and other medicines being taken.

Product Composition: The Role of Dabigatran Etexilate

The active pharmaceutical ingredient in Dabikast-110 is:

• Dabigatran Etexilate 110 mg: An oral anticoagulant that inhibits thrombin and helps prevent the formation and growth of blood clots when used for an appropriate medical indication.

Dabigatran Etexilate is a prodrug that is converted into its active form in the body. Its anticoagulant action helps reduce clot formation, but it can also increase the risk of bleeding. Therefore, it should be taken only as prescribed by a qualified healthcare professional.

Key Uses of Dabigatran Etexilate 110 mg

Depending on the approved indication and the patient’s clinical circumstances, dabigatran may be prescribed for:

1. Stroke Prevention in Atrial Fibrillation: Reducing the risk of stroke and systemic embolism in eligible patients with certain types of non-valvular atrial fibrillation.
2. Treatment of Blood Clots: Treating deep vein thrombosis (DVT) and pulmonary embolism (PE) in appropriate patients.
3. Prevention of Recurrent Blood Clots: Helping reduce the risk of recurrent DVT or PE when continued anticoagulant treatment is indicated.
4. Prevention After Selected Orthopaedic Surgeries: In certain countries and clinical settings, dabigatran is approved for preventing venous blood clots after specific joint-replacement procedures.

Approved uses vary by country and patient circumstances. Consult the product’s approved prescribing information and a healthcare professional to confirm the appropriate indication.

Important Information About Dabikast-110

1. Anticoagulant Action

Dabigatran inhibits thrombin, a key enzyme in the blood-clotting process. This helps reduce the formation of harmful blood clots when treatment is medically indicated.

2. Bleeding Precautions

As an anticoagulant, dabigatran can cause serious bleeding. Seek urgent medical attention for uncontrolled bleeding, black stools, blood in the urine, vomiting blood, or a severe headache following an injury.

3. Kidney Function Considerations

Dabigatran is substantially eliminated through the kidneys. Kidney function should be assessed by a healthcare professional to determine whether the medicine is suitable and what dose is appropriate.

4. Consistent Medical Supervision

Take Dabikast-110 exactly as prescribed. Do not stop treatment, change the dose, or double a missed dose without following your healthcare professional’s instructions.

Why Choose Dabikast-110?

Dabikast-110 is a branded formulation of Dabigatran Etexilate 110 mg. When evaluating this product, healthcare professionals should refer to its verified composition, approved indications, prescribing information, and applicable quality standards.

• Defined Composition: Contains Dabigatran Etexilate 110 mg, as stated in the product name.
• Established Drug Class: Dabigatran belongs to the direct oral anticoagulant (DOAC) class of medicines.
• Prescription-Based Use: Treatment should be selected and monitored by a qualified healthcare professional based on the patient’s condition and risk factors.

How Dabigatran Etexilate Works

After administration, Dabigatran Etexilate is converted into dabigatran, its active form. Dabigatran directly inhibits thrombin, an enzyme responsible for converting fibrinogen into fibrin during blood clot formation. By blocking this process, it reduces the blood’s ability to form clots and helps prevent or treat certain thromboembolic conditions.

Important Safety Precautions

• Bleeding Risk: Inform your doctor about any history of bleeding, ulcers, or bleeding disorders.
• Drug Interactions: Tell your doctor about all medicines you take, especially other anticoagulants, antiplatelet medicines, and certain painkillers.
• Before Surgery or Dental Procedures: Inform your healthcare professional that you take dabigatran. Do not discontinue it on your own.
• Pregnancy and Breastfeeding: Seek medical advice before using this medicine if you are pregnant, planning pregnancy, or breastfeeding.

Summary Table

For more information about Dabikast-110, its availability, or product-related enquiries, please visit the official Novalab Cardiac & Diabetic Care website at www.novalabcardiac.com or contact the company through its verified contact details.

Medical Disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Use Dabigatran Etexilate only under the supervision of a qualified healthcare professional.